GCM
AMLX icon

Graham Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Graham Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
+12,364
New +$191K ﹤0.01% 1004
2025
Q3 		– Sell
-34,153
Closed -$219K – 1226
2025
Q2 		$219K Buy
+34,153
New +$166K ﹤0.01% 1098
2024
Q4 		– Sell
-67,956
Closed -$220K – 1216
2024
Q3 		$220K Sell
67,956
-253,911
-79% -$571K ﹤0.01% 885
2024
Q2 		$612K Sell
321,867
-202,760
-39% -$393K 0.01% 522
2024
Q1 		$1.49M Buy
+524,627
New +$6.86M 0.03% 308
2023
Q4 		– Sell
-56,241
Closed -$1.03M – 983
2023
Q3 		$1.03M Buy
56,241
+25,689
+84% +$543K 0.02% 360
2023
Q2 		$659K Buy
+30,552
New +$825K 0.02% 484

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Graham Capital Management's AMLX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 12,364 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #1004 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in AMLX as recently as Q2 2025.

Graham Capital Management first reported a position in AMLX in Q2 2023 and has held it in 7 quarters since. The position peaked at $1.49M in Q1 2024. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Graham Capital Management held 12,364 shares of Amylyx Pharmaceuticals worth $222K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1004 holding.
  • Graham Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • Graham Capital Management's Amylyx Pharmaceuticals position peaked at $1.49M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.